Bio-Rad Laboratories (BIO) Cash & Equivalents (2009 - 2026)

Bio-Rad Laboratories (BIO) has 18 years of Cash & Equivalents data on file, last reported at $507.2 million in Q1 2026.

• Quarterly Cash & Equivalents fell 2.72% year-over-year to $507.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $507.2 million (down 2.72% YoY) and the FY2025 annual result came in at $529.8 million, up 8.54% from the prior year.
• Cash & Equivalents slipped to $507.2 million in Q1 2026 per BIO's latest filing, from $529.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $802.3 million in Q1 2022 and bottomed at $369.3 million in Q2 2025.
• The 5-year median for Cash & Equivalents is $457.8 million (2023), against an average of $478.2 million.
• The widest annual swing landed in 2023, when Cash & Equivalents plunged 42.15%; it then increased 20.88% in 2024.
• Tracing BIO's Cash & Equivalents over 5 years: stood at $434.2 million in 2022, then dropped by 7.0% to $403.8 million in 2023, then climbed by 20.88% to $488.1 million in 2024, then grew by 8.54% to $529.8 million in 2025, then decreased by 4.27% to $507.2 million in 2026.
• Per Business Quant, the three latest BIO Cash & Equivalents figures stand at $507.2 million (Q1 2026), $529.8 million (Q4 2025), and $395.8 million (Q3 2025).

Peer Comparison